ATAD2 and ovarian cancer: ATAD2, a directed target of miR-302, inhibits APC and promotes nuclear β-catenin expression to reduce the sensitivity of ovarian cancer cells to cisplatin and enhance cisplatin-resistant cell migration, invasion, and EMT abilities [40].